Probiotic with infliximab for Crohn's disease
Part of Digestive system, Immune system & allergy clinical trials.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Crohn's disease.
- You are currently taking infliximab (Remicade) for your Crohn's.
- Your Crohn's is active (symptoms like diarrhea, belly pain, or weight loss).
- You do not have a serious infection, liver/kidney problems, or diabetes that isn't well-controlled.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a special gut bacteria (Akkermansia muciniphila) to the standard biologic treatment infliximab can help heal the lining of the intestine better than infliximab alone. It is for people with active Crohn's disease who have not used biologics or antibiotics recently.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This trial tests whether adding Probiotic 6600 to your usual treatment can help manage colitis, including ulcerative colitis or Crohn's disease. It aims to see if the probiotic improves symptoms and is safe to use.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
Hear when a new Mild to Severe Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.